Figure 1
Flow chart.
Table 1
Baseline angiographic characteristics and post-PCI medications.
| Variables | Total study population | Propensity-matched patients | ||||
|---|---|---|---|---|---|---|
| E-ZES (n = 272) | I-ZES (n = 495) | p | E-ZES (n = 193) | I-ZES (n = 193) | p | |
| Men, n (%) | 192 (70.6) | 346 (69.9) | 0.842 | 136 (70.5) | 134 (69.4) | 0.824 |
| Age (years) | 62.7 ± 10.5 | 64.0 ± 11.2 | 0.131 | 63.2 ± 10.8 | 63.1 ± 11.7 | 0.882 |
| LVEF (%) | 51.0 ± 10.8 | 55.1 ± 8.6 | <0.001 | 53.2 ± 9.8 | 54.1 ± 10.1 | 0.390 |
| Stable angina, n (%) | 60 (22.1) | 133 (26.9) | 0.142 | 45 (23.3) | 58 (30.1) | 0.135 |
| Unstable angina, n (%) | 101 (37.1) | 168 (33.9) | 0.375 | 79 (40.9) | 63 (32.6) | 0.091 |
| ST segment elevation MI, n (%) | 51 (18.8) | 56 (11.3) | 0.004 | 30 (15.5) | 32 (16.6) | 0.782 |
| Non-ST segment elevation MI, n (%) | 38 (14.0) | 103 (20.8) | 0.019 | 25 (13.0) | 29 (15.0) | 0.557 |
| Hypertension, n (%) | 161 (66.5) | 326 (65.9) | 0.848 | 128 (66.3) | 133 (68.9) | 0.587 |
| Diabetes mellitus, n (%) | 78 (28.7) | 188 (38.0) | 0.010 | 55 (28.5) | 67 (34.7) | 0.189 |
| Dyslipidemia, n (%) | 111 (40.8) | 92 (18.6) | <0.001 | 59 (30.6) | 60 (31.1) | 0.912 |
| Previous cerebrovascular accidents, n (%) | 12 (4.4) | 36 (7.3) | 0.118 | 10 (5.2) | 12 (6.2) | 0.827 |
| Previous MI, n (%) | 1 (0.4) | 1 (0.2) | 0.667 | 1 (0.5) | 0 (0.0) | 0.317 |
| Previous PCI, n (%) | 9 (3.3) | 0 (0.0) | <0.001 | 0 (0.0) | 0 (0.0) | – |
| Peripheral vascular disease, n (%) | 6 (2.2) | 25 (5.1) | 0.056 | 3 (1.6) | 4 (2.1) | 0.703 |
| Chronic kidney disease, n (%) | 9 (3.3) | 34 (6.9) | 0.040 | 8 (4.1) | 8 (4.1) | 1.000 |
| Routine angiographic follow-up | 190 (69.9) | 176 (35.6) | <0.001 | 116 (60.1) | 111 (57.5) | 0.605 |
| CK-MB (mg/dL), initial | 31.8 ± 89.0 | 31.5 ± 80.0 | 0.969 | 28.6 ± 87.5 | 42.7 ± 100.5 | 0.159 |
| Troponin T (ng/dL), initial | 0.43 ± 1.41 | 0.55 ± 1.69 | 0.400 | 0.40 ± 1.48 | 0.74 ± 2.17 | 0.130 |
| High sensitivity CRP (mg/dL) | 10.9 ± 23.1 | 7.7 ± 11.1 | 0.015 | 7.2 ± 15.3 | 9.3 ± 14.8 | 0.185 |
| Total cholesterol (mg/L) | 169.5 ± 37.9 | 171.7 ± 45.8 | 0.529 | 168.0 ± 36.5 | 169.4 ± 47.0 | 0.747 |
| Triglyceride (mg/L) | 136.9 ± 75.5 | 147.9 ± 125.0 | 0.307 | 130.2 ± 68.5 | 144.6 ± 95.0 | 0.168 |
| HDL cholesterol (mg/L) | 45.6 ± 12.2 | 44.2 ± 11.0 | 0.190 | 46.1 ± 12.4 | 43.8 ± 11.1 | 0.126 |
| LDL cholesterol (mg/L) | 111.5 ± 34.2 | 108.3 ± 38.0 | 0.391 | 110.8 ± 34.2 | 106.9 ± 39.8 | 0.408 |
| Serum creatinine (mg/L) | 0.97 ± 0.56 | 1.06 ± 1.36 | 0.321 | 0.99 ± 0.65 | 0.99 ± 1.35 | 0.992 |
| Serum glucose (mg/dL) | 117.5 ± 43.2 | 124.6 ± 52.9 | 0.073 | 116.4 ± 45.0 | 122.2 ± 46.6 | 0.245 |
| Hemoglobin A1C (%) | 6.4 ± 1.3 | 6.6 ± 1.3 | 0.108 | 6.4 ± 1.3 | 6.5 ± 1.3 | 0.462 |
| Angiographic characteristics | ||||||
| Targeted vessel | ||||||
| Left anterior descending, n (%) | 155 (57.0) | 310 (62.6) | 0.126 | 111 (57.5) | 113 (58.5) | 0.837 |
| Left circumflex, n (%) | 63 (23.2) | 181 (36.6) | <0.001 | 46 (23.8) | 53(27.5) | 0.415 |
| Right coronary artery, n (%) | 111 (40.8) | 172 (34.7) | 0.096 | 76 (39.4) | 74 (38.3) | 0.835 |
| Left main, n (%) | 9 (3.3) | 14 (2.8) | 0.709 | 6 (3.1) | 6 (3.1) | 1.000 |
| Ramus, n (%) | 2 (0.7) | 8 (1.6) | 0.304 | 1 (0.5) | 3 (1.6) | 0.623 |
| Multi-vessel disease (≥2 vessels) | 60 (22.1) | 156 (31.5) | 0.005 | 42 (21.8) | 48 (24.9) | 0.470 |
| ACC/AHA Lesion type | ||||||
| Type B1, n (%) | 16 (5.9) | 30 (6.1) | 0.921 | 12 (6.2) | 8 (4.1) | 0.492 |
| Type B2, n (%) | 46 (16.9) | 124 (25.1) | 0.009 | 32 (16.6) | 45 (23.3) | 0.098 |
| Type C, n (%) | 210 (77.2) | 340 (68.7) | 0.012 | 149 (77.2) | 139 (72.0) | 0.242 |
| Extent of coronary artery disease, n (%) | ||||||
| 1-vessel | 212 (77.9) | 337 (68.1) | 0.004 | 151 (78.2) | 143 (74.1) | 0.339 |
| 2-vessel | 52 (19.1) | 123 (24.8) | 0.070 | 37 (19.2) | 43 (22.3) | 0.451 |
| 3-vessel | 8 (2.9) | 35 (7.1) | 0.017 | 5 (2.6) | 7 (3.6) | 0.771 |
| Treated CTO | 11 (4.0) | 37 (7.5) | 0.061 | 6 (3.1) | 14 (7.3) | 0.106 |
| Ostial lesion (≤5mm), n (%) | 54 (19.9) | 100 (20.2) | 0.989 | 35 (18.1) | 40 (20.7) | 0.520 |
| Diffuse long lesion (>30mm), n (%) | 123 (45.2) | 211 (42.6) | 0.488 | 83 (43.5) | 87 (45.1) | 0.759 |
| Small vessel disease (≤2.25), n (%) | 15 (5.5) | 77 (15.6) | <0.001 | 13 (6.7) | 19 (9.8) | 0.356 |
| Bifurcation, n (%) | 83 (30.5) | 171 (34.5) | 0.256 | 60 (31.1) | 65 (33.7) | 0.587 |
| Heavy Calcification | 36 (13.2) | 80 (16.2) | 0.279 | 26 (13.5) | 30 (15.5) | 0.563 |
| Mean total stent length (mm) | 23.7 ± 5.8 | 22.2 ± 6.6 | 0.003 | 23.3 ± 5.7 | 23.7 ± 7.1 | 0.532 |
| Mean stent diameter (mm) | 3.09 ± 0.45 | 2.98 ± 0.46 | 0.002 | 3.08 ± 0.45 | 3.06 ± 0.47 | 0.639 |
| Number of stents/patient | 1.31 ± 0.58 | 1.74 ± 1.05 | <0.001 | 1.40 ± 0.72 | 1.48 ± 0.72 | 0.235 |
| Total procedure time (minutes) | 38.5 ± 29.5 | 44.7 ± 29.5 | 0.005 | 36.9 ± 25.4 | 41.8 ± 27.0 | 0.070 |
| Post-PCI medications | ||||||
| Aspirin, n (%) | 253 (93.0) | 461 (93.1) | 0.951 | 182 (94.3) | 180 (93.3) | 0.673 |
| Clopidogrel, n (%) | 249 (91.5) | 447 (90.3) | 0.570 | 182 (94.3) | 177 (91.7) | 0.318 |
| Cilostazol, n (%) | 59 (21.7) | 91 (18.4) | 0.269 | 45 (23.3) | 37 (19.2) | 0.384 |
| Beta blockers, n (%) | 146 (53.7) | 234 (47.3) | 0.090 | 102 (52.8) | 99 (51.3) | 0.760 |
| Calcium channel blockers, n (%) | 96 (35.3) | 187 (37.8) | 0.495 | 63 (32.6) | 70 (36.3) | 0.453 |
| ACEIs, n (%) | 97 (35.7) | 136 (27.5) | 0.018 | 68 (35.2) | 65 (33.7) | 0.748 |
| ARBs, n (%) | 107 (39.3) | 203 (41.0) | 0.652 | 77 (39.9) | 76 (39.4) | 0.917 |
| Diuretics, n (%) | 70 (25.7) | 90 (18.2) | 0.014 | 45 (23.3) | 44 (22.8) | 0.904 |
| Lipid lowering agents, n (%) | 233 (85.7) | 435 (87.9) | 0.381 | 171 (88.6) | 173 (89.6) | 0.744 |
[i] Values are mean ± SD or n (%). The p values for continuous data obtained from analysis of variance. The p values for categorical data obtained from chi-square test.
E, Endeavor®; I, Resolute Integrity®; ZES, zotarolimus-eluting stent; LVEF, left ventricular ejection fraction; MI, myocardial infarction; CK-MB, creatine kinase myocardial band; CRP, C-reactive protein; HDL, high-density lipoprotein; LDL, low-density lipoprotein; ACC/AHA, American college of cardiology/American heart association; CTO, chronic total occlusive lesion. PCI, percutaneous coronary intervention; ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers.
Table 2
Clinical outcomes at 30 days, 1 year, and 3 years.
| Outcomes | Total study population | Propensity-matched patients | |||||
|---|---|---|---|---|---|---|---|
| Total (n = 767) | E-ZES (n = 272) | I-ZES (n = 495) | p | E-ZES (n = 193) | I-ZES (n = 193) | p | |
| 30 days | |||||||
| MACEs | 11 (1.4) | 4 (1.5) | 7 (1.4) | 0.950 | 4 (2.1) | 1 (0.5) | 0.177 |
| All-cause death, n (%) | 7 (0.9) | 2 (0.7) | 5 (1.0) | 0.702 | 2 (1.0) | 0 (0.0) | 0.156 |
| Cardiac death, n (%) | 6 (0.8) | 2 (0.7) | 4 (0.8) | 0.913 | 2 (1.0) | 0 (0.0) | 0.156 |
| Non-fatal MI, n (%) | 6 (0.8) | 3 (1.1) | 3 (0.6) | 0.672 | 3 (1.6) | 1 (0.5) | 0.623 |
| Any revascularization, n (%) | 6 (0.8) | 2 (0.7) | 4 (0.8) | 0.913 | 2 (1.0) | 1 (0.5) | 0.562 |
| TLR, n (%) | 5 (0.7) | 2 (0.7) | 3 (0.6) | 0.832 | 2 (1.0) | 1 (0.5) | 0.562 |
| TVR, n (%) | 6 (0.8) | 2 (0.7) | 4 (0.8) | 0.913 | 2 (1.0) | 1 (0.5) | 0.562 |
| Non-TVR, n (%) | 1 (0.1) | 1 (0.4) | 0 (0.0) | 0.355 | 1 (0.5) | 0 (0.0) | 0.317 |
| ST (definite or probable), n (%) | |||||||
| Acute, n (%) | 2 (0.3) | 1 (0.4) | 1 (0.2) | 0.667 | 1 (0.5) | 1 (0.5) | 1.000 |
| Subacute, n (%) | 4 (0.5) | 2 (0.7) | 2 (0.4) | 0.542 | 2 (1.0) | 1 (0.5) | 0.562 |
| Total, n (%) | 6 (0.8) | 3 (1.1) | 3 (0.6) | 0.672 | 3 (1.6) | 2 (1.0) | 0.653 |
| 1-year | |||||||
| MACEs, n (%) | 61 (8.0) | 29 (10.7) | 32 (6.5) | 0.040 | 13 (6.7) | 13 (6.7) | 1.000 |
| All-cause death, n (%) | 22 (2.9) | 10 (3.7) | 12 (2.4) | 0.320 | 8 (4.1) | 7 (3.6) | 0.792 |
| Cardiac death, n (%) | 16 (2.1) | 7 (2.6) | 9 (1.8) | 0.598 | 5 (2.6) | 5 (2.6) | 1.000 |
| Non-fatal MI, n (%) | 9 (1.2) | 5 (1.8) | 4 (0.8) | 0.292 | 4 (2.1) | 1 (0.5) | 0.177 |
| Any revascularization, n (%) | 45 (5.9) | 21 (7.7) | 24 (4.8) | 0.105 | 7 (3.6) | 8 (4.1) | 0.792 |
| TLR, n (%) | 30 (3.9) | 17 (6.3) | 13 (2.6) | 0.013 | 6 (3.1) | 5 (2.6) | 0.760 |
| TVR, n (%) | 38 (5.0) | 20 (7.4) | 18 (3.6) | 0.023 | 7 (3.6) | 7 (3.6) | 1.000 |
| Non-TVR, n (%) | 9 (1.2) | 5 (1.8) | 4 (0.8) | 0.292 | 2 (1.0) | 0 (0.0) | 0.156 |
| ST (definite or probable), n (%) | |||||||
| Late (31–365 days) | 1 (0.1) | 1 (0.4) | 0 (0.0) | 0.177 | 1 (0.5) | 0 (0.0) | 0.317 |
| Total (1–365 days) | 7 (0.9) | 4 (1.5) | 3 (0.6) | 0.253 | 4 (2.1) | 2 (1.0) | 0.685 |
| 3-year | |||||||
| MACEs, n (%) | 90 (11.7) | 42 (15.4) | 48 (9.7) | 0.018 | 25 (13.0) | 20 (10.4) | 0.428 |
| All-cause death, n (%) | 31 (1.0) | 17 (6.3) | 14 (2.8) | 0.021 | 15 (7.8) | 7 (3.6) | 0.079 |
| Cardiac death, n (%) | 19 (2.5) | 10 (3.7) | 9 (1.8) | 0.113 | 8 (4.1) | 5 (2.6) | 0.574 |
| Non-fatal MI, n (%) | 20 (2.6) | 11 (4.0) | 9 (1.8) | 0.095 | 10 (5.2) | 4 (2.1) | 0.172 |
| Any revascularization, n (%) | 59 (7.7) | 25 (9.2) | 34 (6.9) | 0.248 | 10 (5.2) | 12 (6.2) | 0.661 |
| TLR, n (%) | 38 (5.0) | 19 (7.0) | 19 (3.8) | 0.055 | 7 (3.6) | 7 (3.6) | 1.000 |
| TVR, n (%) | 54 (7.0) | 24 (8.8) | 30 (6.1) | 0.152 | 10 (5.2) | 12 (6.2) | 0.661 |
| Non-TVR, n (%) | 11 (1.4) | 5 (1.8) | 6 (1.2) | 0.532 | 2 (1.0) | 1 (0.5) | 0.562 |
| ST (definite or probable), n (%) | |||||||
| Very late (366–1095 days) | 1 (0.1) | 1 (0.4) | 0 (0.0) | 0.177 | 1 (0.5) | 0 (0.0) | 0.317 |
| Total (1–1095 days) | 8 (1.0) | 5 (1.8) | 3 (0.6) | 0.140 | 5 (2.6) | 2 (1.0) | 0.449 |
[i] Values are numbers and percentages. The p values for categorical data obtained from chi-square test.
E, Endeavor®; I, Resolute Integrity®; ZES, zotarolimus-eluting stent; MACEs, major adverse cardiac events; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization.
Figure 2
Kaplan-Meier curved analysis for MACE-free survival (A, B), and stent thrombosis (C, D) at 3 years.
Table 3
Three-Year Clinical Outcomes by Kaplan–Meier Curved Analysis and Cox-proportional Hazard Ratio Model Analysis.
| Outcomes | Cumulative Events at 3 years (%) | Hazard Ratio (95% CI) | p | ||
|---|---|---|---|---|---|
| E-ZES | I-ZES | Log Rank | |||
| Total study population | |||||
| MACEs | 42 (15.6) | 48 (10.5) | 0.036 | 0.644 (0.425–0.975) | 0.038 |
| All-cause death | 17 (6.2) | 14 (2.9) | 0.034 | 0.474 (0.233–0.962) | 0.039 |
| Cardiac death | 10 (3.7) | 9 (1.8) | 0.137 | 0.511 (0.207–1.259) | 0.144 |
| Non-fatal MI | 11 (4.1) | 9 (2.1) | 0.110 | 0.494 (0.204–1.195) | 0.118 |
| Any revascularization | 25 (9.5) | 34 (7.4) | 0.284 | 0.755 (0.450–1.266) | 0.286 |
| TLR | 19 (7.1) | 19 (4.2) | 0.065 | 0.554 (0.293–1.048) | 0.069 |
| TVR | 24 (9.0) | 30 (6.7) | 0.204 | 0.707 (0.413–1.211) | 0.207 |
| Non-TVR | 5 (1.9) | 6 (1.3) | 0.495 | 0.663 (0.202–2.174) | 0.498 |
| Stent thrombosis | 5 (1.8) | 3 (0.6) | 0.108 | 0.328 (0.078–1.373) | 0.127 |
| Propensity-matched patients | |||||
| MACEs | 25 (13.1) | 20 (11.0) | 0.553 | 0.837 (0.464–1.508) | 0.553 |
| All-cause death | 15 (7.8) | 7 (3.6) | 0.104 | 0.482 (0.196–1.183) | 0.111 |
| Cardiac death | 8 (4.2) | 5 (2.6) | 0.432 | 0.641 (0.210–1.961) | 0.436 |
| Non-fatal MI | 10 (5.3) | 4 (2.3) | 0.140 | 0.428 (0.134–1.367) | 0.152 |
| Any revascularization | 10 (5.4) | 12 (6.5) | 0.622 | 1.235 (0.533–2.862) | 0.623 |
| TLR | 7 (3.7) | 7 (3.9) | 0.991 | 1.006 (0.353–2.869) | 0.991 |
| TVR | 10 (5.3) | 12 (6.6) | 0.598 | 1.253 (0.541–2.904) | 0.599 |
| Non-TVR | 2 (1.1) | 1 (0.6) | 0.578 | 0.512 (0.046–5.653) | 0.585 |
| Stent thrombosis | 5 (2.6) | 2 (1.0) | 0.254 | 0.398 (0.077–2.052) | 0.271 |
| Multivariate analysis* | |||||
| MACEs | 42 (15.6) | 48 (10.5) | 0.036 | 0.943 (0.559–1.563) | 0.820 |
| All-cause death | 17 (6.2) | 14 (2.9) | 0.034 | 0.433 (0.175–1.070) | 0.070 |
| Cardiac death | 10 (3.7) | 9 (1.8) | 0.137 | 0.597 (0.191–1.863) | 0.374 |
| Non-fatal MI | 11 (4.1) | 9 (2.1) | 0.110 | 0.481 (0.164–1.408) | 0.182 |
| Any revascularization | 25 (9.5) | 34 (7.4) | 0.284 | 1.374 (0.721–2.614) | 0.334 |
| TLR | 19 (7.1) | 19 (4.2) | 0.065 | 1.138 (0.515–2.512) | 0.749 |
| TVR | 24 (9.0) | 30 (6.7) | 0.204 | 1.322 (0.677–2.584) | 0.414 |
| Non-TVR | 2 (1.1) | 1 (0.6) | 0.578 | 0.697 (0.163–2.984) | 0.627 |
| Stent thrombosis | 5 (2.6) | 2 (1.0) | 0.254 | 0.536 (0.103–2.788) | 0.459 |
[i] * Adjusted by age, men, LVEF, STEMI, NSTEMI, diabetes, dyslipidemia, previous history of PCI, CKD, routine angiographic follow-up, serum level of hs-CRP, LCx (targeted vessel), multi-vessel disease, ACC/AHA type B2/C lesion, 1-vessel disease, 3-vessel disease, small vessel disease, mean total stent length, mean stent diameter, number of stents/patient, total procedure time, ACEIs, diuretics.
E, Endeavor®; I, Resolute Integrity®; ZES, zotarolimus-eluting stent; CI, confidence interval; MACEs, major adverse cardiac events; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization; CKD, chronic kidney disease; hs-CRP, high-sensitivity C-reactive protein; LCx, left circumflex artery; ACC/AHA, American College of Cardiology/American Heart Association; PCI, percutaneous coronary intervention; ACEIs, angiotensin converting enzyme inhibitors.
Table 4
Outcome incidence rates according to time to event.
| MACEs | All-cause death | Cardiac death | Non-fatal MI | Any revascularization | TLR | TVR | Non-TVR | Stent thrombosis | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| E-ZES | I-ZES | E-ZES | I-ZES | E-ZES | I-ZES | E-ZES | I-ZES | E-ZES | I-ZES | E-ZES | I-ZES | E-ZES | I-ZES | E-ZES | I-ZES | E-ZES | I-ZES | |
| Total study population (n = 767) E-ZES (n = 272), I-ZES (n = 495) | ||||||||||||||||||
| Number of events, n (%) | 42 | 48 | 17 | 14 | 10 | 9 | 11 | 9 | 25 | 34 | 19 | 19 | 24 | 30 | 5 | 6 | 5 | 3 |
| Number of events/patients | 0.15 | 0.10 | 0.06 | 0.03 | 0.04 | 0.02 | 0.04 | 0.02 | 0.09 | 0.07 | 0.07 | 0.04 | 0.09 | 0.06 | 0.02 | 0.001 | 0.02 | 0.01 |
| Time to event (days), n (%) | ||||||||||||||||||
| 1–7 | 3 (7) | 3 (6) | 1 (6) | 2 (14) | 1 (10) | 2 (22) | 2 (18) | 1 (11) | 2 (8) | 0 | 2 (11) | 0 | 2 (8) | 0 | 1 (20) | 0 | 3 (60) | 1 (33) |
| 8–30 | 1 (2) | 4 (8) | 1 (6) | 3 (21) | 1 (10) | 2 (22) | 1 (9) | 2 (22) | 0 | 4 (12) | 0 | 3 (16) | 0 | 4 (13) | 0 | 0 | 0 | 2 (67) |
| 31–180 | 9 (21) | 11 (23) | 4 (24) | 4 (29) | 3 (30) | 2 (22) | 2 (18) | 1 (11) | 7 (28) | 8 (24) | 5 (26) | 5 (26) | 7 (29) | 7 (23) | 0 | 1 (17) | 1 (20) | 0 |
| 181–365 | 16 (38) | 14 (29) | 4 (24) | 3 (21) | 2 (20) | 3 (33) | 0 | 0 | 12 (48) | 12 (35) | 10 (53) | 5 (26) | 11 (46) | 7 (23) | 4 (80) | 3 (50) | 0 | 0 |
| 366–548 | 5 (12) | 5 (10) | 3 (18) | 1 (7) | 1 (10) | 0 | 2 (18) | 2 (22) | 2 (8) | 3 (9) | 2 (11) | 2 (11) | 2 (8) | 3 (10) | 0 | 0 | 1 (20) | 0 |
| 549–730 | 3 (7) | 7 (15) | 1 (6) | 1 (7) | 0 | 0 | 1 (9) | 1 (11) | 0 | 5 (15) | 0 | 2 (11) | 0 | 5 (17) | 0 | 2 (33) | 0 | 0 |
| 731–913 | 3 (7) | 2 (4) | 2 (12) | 0 | 2 (20) | 0 | 3 (27) | 2 (22) | 1 (4) | 1 (3) | 0 | 1 (5) | 1 (4) | 3 (10) | 0 | 0 | 0 | 0 |
| 914–1095 | 2 (5) | 2 (4) | 0 | 0 | 0 | 0 | 0 | 0 | 1 (4) | 1 (3) | 0 | 1 (5) | 1 (4) | 1 (3) | 0 | 0 | 0 | 0 |
| Propensity-matched patients (n = 386) E-ZES (n = 193), I-ZES (n = 193) | ||||||||||||||||||
| Number of events, n (%) | 25 | 20 | 15 | 7 | 8 | 5 | 10 | 4 | 10 | 12 | 7 | 7 | 10 | 12 | 2 | 1 | 5 | 2 |
| Number of events/patients | 0.13 | 0.10 | 0.08 | 0.04 | 0.04 | 0.03 | 0.05 | 0.02 | 0.05 | 0.06 | 0.04 | 0.04 | 0.05 | 0.06 | 0.01 | 0.01 | 0.03 | 0.01 |
| Time to event (days), n (%) | ||||||||||||||||||
| 1–7 | 3 (12) | 0 | 1 (7) | 0 | 1 (13) | 0 | 2 (20) | 0 | 2 (20) | 0 | 2 (29) | 0 | 2 (20) | 0 | 1 (50) | 0 | 3 (60) | 1 (33) |
| 8–30 | 1 (4) | 1 (5) | 1 (7) | 0 | 1 (13) | 0 | 1 (10) | 1 (25) | 0 | 1 (8) | 0 | 1 (16) | 0 | 1 (8) | 0 | 0 | 0 | 1 (67) |
| 31–180 | 5 (20) | 7 (35) | 4 (27) | 4 (57) | 3 (38) | 2 (40) | 1 (10) | 0 | 3 (30) | 4 (33) | 2 (29) | 1 (26) | 3 (30) | 3 (25) | 0 | 0 | 1 (20) | 0 |
| 181–365 | 4 (16) | 5 (25) | 2 (13) | 3 (43) | 0 | 3 (60) | 0 | 0 | 2 (20) | 3 (25) | 2 (29) | 3 (26) | 2 (20) | 3 (25) | 1 (50) | 0 | 0 | 0 |
| 366–548 | 4 (16) | 3 (15) | 2 (13) | 0 | 1 (13) | 0 | 2 (20) | 1 (25) | 1 (10) | 2 (17) | 1 (14) | 1 (11) | 1 (10) | 2 (17) | 0 | 0 | 1 (20) | 0 |
| 549–730 | 3 (12) | 3 (15) | 2 (13) | 0 | 0 | 0 | 1 (10) | 1 (25) | 0 | 2 (17) | 0 | 0 | 0 | 2 (17) | 0 | 1 (100) | 0 | 0 |
| 731–913 | 3 (12) | 0 | 2 (13) | 0 | 2 (25) | 0 | 3 (30) | 1 (25) | 1 (10) | 0 | 0 | 1 (5) | 1 (10) | 1 (8) | 0 | 0 | 0 | 0 |
| 914–1095 | 2 (8) | 1 (5) | 1 (7) | 0 | 0 | 0 | 0 | 0 | 1 (10) | 0 | 0 | 0 | 1 (10) | 0 | 0 | 0 | 0 | |
[i] E, Endeavor®; I, Resolute Integrity®; ZES, zotarolimus-eluting stent; MACEs, major adverse cardiac events; MI, myocardial infarction; TLR, target lesion revascularization; TVR, target vessel revascularization.
Figure 3
Subgroup analyses for MACEs.